| Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| WILLSEY LANCE | Director | May 12 | Option Exercise | 3.13 | 40,000 | 125,200 | 464,415 | May 13 08:10 PM | | WILLSEY LANCE | Director | May 12 | Sale | 19.65 | 40,000 | 786,000 | 424,415 | May 13 08:10 PM | | WYSZOMIERSKI JACK L | Director | Apr 04 | Option Exercise | 3.13 | 40,000 | 125,200 | 279,888 | Apr 06 08:08 PM | | WYSZOMIERSKI JACK L | Director | Apr 04 | Sale | 23.00 | 6,696 | 154,008 | 273,192 | Apr 06 08:08 PM | | Haley Patrick J. | EVP, Commercial | Apr 01 | Option Exercise | 6.21 | 10,000 | 62,100 | 279,191 | Apr 04 08:11 PM | | Haley Patrick J. | EVP, Commercial | Apr 01 | Sale | 23.00 | 10,000 | 230,000 | 269,191 | Apr 04 08:11 PM | | Haley Patrick J. | EVP, Commercial | Mar 31 | Option Exercise | 6.21 | 10,000 | 62,100 | 279,191 | Apr 04 08:11 PM | | Haley Patrick J. | EVP, Commercial | Mar 31 | Sale | 22.43 | 10,000 | 224,300 | 269,191 | Apr 04 08:11 PM | | Hessekiel Jeffrey | EVP, General Counsel & Sec | Mar 29 | Sale | 22.00 | 13,283 | 292,226 | 605,236 | Mar 30 08:17 PM | | Hessekiel Jeffrey | EVP, General Counsel & Sec | Mar 28 | Sale | 22.00 | 4,717 | 103,774 | 618,519 | Mar 30 08:17 PM | | Garber Alan M | Director | Mar 01 | Option Exercise | 3.13 | 40,000 | 125,200 | 52,718 | Mar 03 08:07 PM | | Garber Alan M | Director | Mar 01 | Sale | 21.00 | 21,301 | 447,321 | 31,417 | Mar 03 08:07 PM | | Haley Patrick J. | EVP, Commercial | Feb 25 | Sale | 19.53 | 31,238 | 610,078 | 198,476 | Feb 28 08:09 PM | | Hessekiel Jeffrey | EVP and General Counsel | Feb 24 | Sale | 20.00 | 18,000 | 360,000 | 555,361 | Feb 28 08:11 PM | | FELDBAUM CARL B | Director | Feb 22 | Option Exercise | 3.13 | 20,000 | 62,600 | 28,521 | Feb 24 08:20 PM | | PAPADOPOULOS STELIOS | Director | Feb 22 | Sale | 19.56 | 84,515 | 1,653,113 | 1,220,036 | Feb 24 08:22 PM | | FELDBAUM CARL B | Director | Feb 22 | Sale | 19.49 | 20,000 | 389,800 | 8,521 | Feb 24 08:20 PM | | Haley Patrick J. | EVP, Commercial | Feb 03 | Option Exercise | 1.90 | 60,000 | 114,000 | 305,241 | Feb 04 09:52 PM | | Haley Patrick J. | EVP, Commercial | Feb 03 | Sale | 17.91 | 60,000 | 1,074,600 | 245,241 | Feb 04 09:52 PM | | Lamb Peter | EVP, Scientific Strategy & CSO | Dec 15 | Option Exercise | 6.21 | 47,500 | 294,975 | 410,672 | Dec 17 08:35 PM | | Lamb Peter | EVP, Scientific Strategy & CSO | Dec 15 | Sale | 17.44 | 47,500 | 828,400 | 363,172 | Dec 17 08:35 PM | | Haley Patrick J. | EVP, Commercial | Nov 24 | Sale | 17.25 | 17,236 | 297,321 | 237,802 | Nov 26 07:39 PM | | FELDBAUM CARL B | Director | Nov 19 | Option Exercise | 3.13 | 20,000 | 62,600 | 28,521 | Nov 23 08:11 PM | | FELDBAUM CARL B | Director | Nov 19 | Sale | 17.62 | 20,000 | 352,400 | 8,521 | Nov 23 08:11 PM | | Lamb Peter | EVP, Scientific Strategy & CSO | Nov 15 | Option Exercise | 6.21 | 47,500 | 294,975 | 458,740 | Nov 17 08:02 PM | | Lamb Peter | EVP, Scientific Strategy & CSO | Nov 15 | Sale | 18.09 | 47,500 | 859,275 | 411,240 | Nov 17 08:02 PM | | Hessekiel Jeffrey | EVP and General Counsel | Nov 01 | Sale | 22.03 | 5,117 | 112,728 | 632,825 | Nov 03 08:12 PM | | Lamb Peter | EVP, Scientific Strategy & CSO | Oct 15 | Option Exercise | 6.21 | 47,500 | 294,975 | 458,740 | Oct 15 08:15 PM | | Lamb Peter | EVP, Scientific Strategy & CSO | Oct 15 | Sale | 21.92 | 47,500 | 1,041,200 | 411,240 | Oct 15 08:15 PM | | Hessekiel Jeffrey | EVP and General Counsel | Oct 15 | Sale | 22.02 | 12,883 | 283,684 | 637,942 | Oct 15 08:14 PM | | Senner Christopher J. | EVP and CFO | Sep 21 | Option Exercise | 3.66 | 90,000 | 329,400 | 446,591 | Sep 23 08:16 PM | | Haley Patrick J. | EVP, Commercial | Sep 16 | Option Exercise | 1.70 | 25,000 | 42,500 | 305,994 | Sep 17 07:58 PM | | Haley Patrick J. | EVP, Commercial | Sep 16 | Sale | 20.36 | 25,000 | 509,000 | 280,994 | Sep 17 07:58 PM | | Lamb Peter | EVP, Scientific Strategy & CSO | Sep 15 | Option Exercise | 6.21 | 47,500 | 294,975 | 436,967 | Sep 17 07:56 PM | | Lamb Peter | EVP, Scientific Strategy & CSO | Sep 15 | Sale | 20.46 | 47,500 | 971,850 | 389,467 | Sep 17 07:56 PM | | Lamb Peter | EVP, Scientific Strategy & CSO | Aug 16 | Option Exercise | 1.90 | 55,000 | 104,500 | 444,467 | Aug 18 07:56 PM | | Lamb Peter | EVP, Scientific Strategy & CSO | Aug 16 | Sale | 18.44 | 55,000 | 1,014,200 | 389,467 | Aug 18 07:56 PM | | Schwab Gisela | Pres, Prod Dev & Med Aff & CMO | Jul 26 | Option Exercise | 4.20 | 40,000 | 168,000 | 689,078 | Jul 28 08:06 PM | | Schwab Gisela | Pres, Prod Dev & Med Aff & CMO | Jul 21 | Option Exercise | 4.20 | 35,000 | 147,000 | 649,078 | Jul 23 07:47 PM | | Lamb Peter | EVP, Scientific Strategy & CSO | Jul 15 | Option Exercise | 1.90 | 60,000 | 114,000 | 449,467 | Jul 16 07:58 PM | | Lamb Peter | EVP, Scientific Strategy & CSO | Jul 15 | Sale | 17.47 | 60,000 | 1,048,200 | 389,467 | Jul 16 07:58 PM | | COHEN CHARLES | Director | Jul 06 | Option Exercise | 4.71 | 80,000 | 377,200 | 261,375 | Jul 08 07:45 PM | | Lamb Peter | EVP, Scientific Strategy & CSO | Jun 17 | Option Exercise | 1.90 | 60,000 | 114,000 | 449,467 | Jun 22 08:03 PM | | Lamb Peter | EVP, Scientific Strategy & CSO | Jun 17 | Sale | 22.18 | 60,000 | 1,330,800 | 389,467 | Jun 22 08:03 PM |
|
